Overview A Study of 1592U89 in HIV-Infected Patients Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood). Phase: Phase 1 Details Lead Sponsor: Glaxo WellcomeTreatments: Abacavir